Casein Kinase

Casein Kinases (CKs), a group of ubiquitous Ser/Thr kinases, regulate a wide range of cellular functions in eukaryotes, including phosphorylation of proteins that are substrates for degradation via the ubiquitin-proteasome system (UPS). Two casein kinases, casein kinase-1 (CK-1) and casein kinase-2 (CK-2), have been characterized from many sources.

CK1 kinases exist in at least seven isoforms (α, β, γ1-3, δ, and ε) in mammals and CK1 kinases phosphorylate various substrates to play vital roles in diverse physiological processes such as DNA repair, cell cycle progression, cytokinesis, differentiation, and apoptosis. Casein kinase 2 (CK2) is a highly pleiotropic serine-threonine kinase, which catalyzed phosphorylation of more than 300 proteins that are implicated in regulation of many cellular functions, such as signal transduction, transcriptional control, apoptosis, and the cell cycle.

Casein Kinase Inhibitors & Activators

(E/Z)-GO289

Cat. No.: HY-115519

(E/Z)-GO289 is a potent and selective **casein kinase 2 (CK2)** inhibitor (IC_{50}=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

4,5,6,7-Tetrabromo-1H-benzimidazole

Cat. No.: HY-W042648

4,5,6,7-Tetrabromobenzimidazole is a selective and ATP competitive **CK2** (casein kinase 2) inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A-3 hydrochloride

Cat. No.: HY-125957

A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various **kinases**. It against PKA (K_i=4.3 μM), casein kinase II (K_i=5.1 μM) and myosin light chain kinase (MLCK) (K_i=7.4 μM).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AMG-548

Cat. No.: HY-108642

AMG-548, an orally active and selective **p38α** inhibitor (K_i=0.5 nM), shows slightly selective over **p38β** (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated **TNFα** (IC_{50}=3 nM).



Purity: ≥99.0%
Clinical Data:
Size: 1 mg, 5 mg

AMG-548 dihydrochloride

Cat. No.: HY-108642B

AMG-548 dihydrochloride, an orally active and selective **p38α** inhibitor (K_i=0.5 nM), shows slightly selective over **p38β** (K_i=36 nM) and >1000 fold selective against p38γ and p38δ.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AMG-548 hydrochloride

Cat. No.: HY-108642A

AMG-548 hydrochloride, an orally active and selective **p38α** inhibitor (K_i=0.5 nM), shows slightly selective over **p38β** (K_i=36 nM) and >1000 fold selective against p38γ and p38δ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BioE-1115

Cat. No.: HY-129571

BioE-1115 is a highly selective and potent **PAS kinase (PASK)** inhibitor with an IC_{50} of ~4 nM. BioE-1115 is also a potent **casein kinase 2α** inhibitor with an IC_{50} of ~10 μM.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BRD4/CK2-IN-1

Cat. No.: HY-145260

BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of **BRD4/CK2** (bromodomain-containing protein 4/casein kinase 2), with IC_{50}s of 180 nM and 230 nM for BRD4 and CK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTX161

Cat. No.: HY-120084

BTX161, a Thalidomide analog, is a potent **CKIα** degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Casein Kinase II Inhibitor IV

Cat. No.: HY-111378

Casein Kinase II Inhibitor IV is a small-molecule inducer of epidermal keratinocyte differentiation.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Casein Kinase II Inhibitor IV Hydrochloride

Cat. No.: HY-111378A

Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocyte differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Casein Kinase inhibitor A51

Cat. No.: HY-123954

Casein Kinase inhibitor A51 is a potent and orally active **casein kinase 1α (CK1α)** inhibitor. Casein Kinase inhibitor A51 induces leukemia cell **apoptosis**, and has potent anti-leukemic activities.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Casein Kinase inhibitor A86

Cat. No.: HY-123955

Casein Kinase inhibitor A86 is a potent and orally active **casein kinase 1α (CK1α)** inhibitor. Casein Kinase inhibitor A86 also inhibits of **CDK7 (TFIIH)** and **CDK9 (P-TEFb)**. Casein Kinase inhibitor A861 induces leukemia cell **apoptosis**, and has potent anti-leukemic activities.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CK1-IN-1

Cat. No.: HY-111820

CK1-IN-1 is a **casein kinase 1 (CK1)** inhibitor extracted from patent WO2015119579A1, compound 1c, has IC_{50}s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CK2 inhibitor 2

Cat. No.: HY-132175

CK2 inhibitor 2 is a potent, selective and orally active inhibitor of **CK2**, with an IC_{50} of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC_{50}=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CK2 inhibitor 3

Cat. No.: HY-143461

CK2 inhibitor 3 is a potent **CK2** inhibitor with IC_{50} value of 280 nM. CK2 inhibitor 3 inhibits endocellular CK2, significantly affects viability of tumour cells and shows remarkable selectivity on a panel of 320 kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CK2/ERK8-IN-1

Cat. No.: HY-135906

CK2/ERK8-IN-1 is a dual **casein kinase 2 (CK2)** (K_i of 0.25 μM) and **ERK8** (MAPK15, ERK7) inhibitor with IC_{50}s of 0.50 μM. CK2/ERK8-IN-1 also binds to **PIM1**, **HIPK2** (**homeodomain-interacting protein kinase 2**), and **DYRK1A** with K_is of 8.65 μM, 15.25 μM, and 11.9 μM, respectively.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CK2/PIM1-IN-1

Cat. No.: HY-135816

CK2/PIM1-IN-1 is an inhibitor of **CK2** and **PIM1**, with IC_{50}s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CKI-7

Cat. No.: HY-W011109

CKI-7 is a potent and ATP-competitive **casein kinase 1 (CK1)** inhibitor with an IC_{50} of 6 μM and a K_i of 8.5 μM. CKI-7 is a selective **Cdc7 kinase** inhibitor. CKI-7 also inhibits **SGK**, **ribosomal S6 kinase-1 (S6K1)** and **mitogen- and stress-activated protein kinase-1 (MSK1)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CKI-7 free base

Cat. No.: HY-133028

CKI-7 free base is a potent and ATP-competitive **casein kinase 1 (CK1)** inhibitor with an IC_{50} of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective **Cdc7 kinase** inhibitor.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

D4476

(Casein Kinase I Inhibitor) Cat. No.: HY-10324

D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(**CK1**) with an IC_{50} value of 0.3 μM in vitro.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

DMAT

(CK2 Inhibitor; Casein kinase II Inhibitor) Cat. No.: HY-15535

DMAT is a potent and specific **CK2** inhibitor with an IC_{50} value of 130 nM.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ellagic acid

Cat. No.: HY-B0183

Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive **CK2** inhibitor, with an IC_{50} of 40 nM and a K_i of 20 nM.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ellagic acid (hydrate)

Cat. No.: HY-B0183A

Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive **CK2** inhibitor, with an IC_{50} of 40 nM and a K_i of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emodin

(Frangula emodin) Cat. No.: HY-14393

Emodin (Frangula emodin), an anthraquinone derivative, is an anti-**SARS-CoV** compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits **casein kinase-2** (**CK2**). Anti-inflammatory and anticancer effects.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Emodin-d4

(Frangula emodin-d4) Cat. No.: HY-14393S

Emodin-d4 (Frangula emodin-d4) is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-**SARS-CoV** compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Epiblastin A

Cat. No.: HY-114858

Epiblastin A is an ATP competitive **casein kinase 1** (**CK1**) inhibitor with IC_{50}s of 8.9, 0.5, and 4.7 μM for CK1α, CK1δ, and CK1 ε, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FPFT-2216

Cat. No.: HY-145319

FPFT-2216, a "molecular glue" compound, degrades phosphodiesterase 6D (**PDE6D**), zinc finger transcription factors Ikaros (**IKZF1**), Aiolos (**IKZF3**), and casein kinase 1α (**CK1α**). FPFT-2216 can be used for the research of cancer and inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Hematein

Cat. No.: HY-119751

Hematein is a oxidation product of hematoxylin acted as a dye. Hematein is an allosteric **casein kinase II** inhibitor with an IC_{50} of 0.74 μM. Hematein inhibits **Akt/PKB Ser129** phosphorylation, the **Wnt/TCF** pathway and increases **apoptosis** in lung cancer cells.



Purity: 74.90%
Clinical Data:
Size: 10 mM × 1 mL, 500 mg, 1 g

IC261

Cat. No.: HY-12774

IC261 is a selective, ATP-competitive **CK1** inhibitor, with IC_{50}s of 1 μM, 1 μM, 16 μM for **Ckiδ**, **Ckiε** and Ckiα1, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IWP-2

Cat. No.: HY-13912

IWP-2 is an inhibitor of **Wnt** processing and secretion with an **IC_{50}** of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LH846

Cat. No.: HY-15704

LH846 is a selective inhibitor of **CKIδ**, with an **IC_{50}** of 290 nM, and less potently inhibits CKIα and CKIε, with **IC_{50}**s of 2.5 μM and 1.3 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Longdaysin

Cat. No.: HY-18285

Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits **CK1α**, **CK1δ**, **CDK7**, and **ERK2** with **IC_{50}**s of 5.6 μM, 8.8 μM, 29 μM, and 52 μM, respectively.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY294002

Cat. No.: HY-10108

LY294002 is a broad-spectrum inhibitor of **PI3K** with **IC_{50}**s of 0.5, 0.57, and 0.97 μM for **PI3Kα**, **PI3Kδ** and **PI3Kβ**, respectively. LY294002 also inhibits **CK2** with an **IC_{50}** of 98 nM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

MRT00033659

Cat. No.: HY-117857

MRT00033659 is a potent broad-spectrum kinase inhibitor of **CK1** (**IC_{50}**=0.9 μM for CK1δ) and **CHK1** (**IC_{50}**=0.23 μM). MRT00033659, a pyrazolo-pyridine analogue, induces **p53** pathway activation and E2F-1 destabilisation.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NCC007

Cat. No.: HY-128677

NCC007 is a dual **casein kinase Iα (CKIα)** and **δ (CKIδ)** inhibitor with **IC_{50}**s of 1.8 and 3.6 μM, respectively. NCC007 can be used in research of modulating mammalian circadian rhythms.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orobol

Cat. No.: HY-N3127

Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits **CK1ε**, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (**IC_{50}**=1.24-4.45 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PF-4800567

Cat. No.: HY-12470

PF-4800567 is a potent and selective inhibitor of casein kinase 1ε (**CK1ε**), with an **IC_{50}** of 32 nM, which is greater than 20-fold selectivity over CK1δ (**IC_{50}**, 711 nM).



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-5006739

Cat. No.: HY-12443

PF-5006739 is a potent and selective inhibitor of **CK1δ/ε** with **IC_{50}**s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-670462

Cat. No.: HY-15490

PF-670462 is a potent and selective inhibitor of **casein kinase (CK1ε and CK1δ)**, with **IC_{50}**s of 7.7 nM and 14 nM, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PI-828

Cat. No.: HY-108606

PI-828 is a dual **PI3K** and **casein kinase 2** (**CK2**) inhibitor with IC_{50}s of 173 nM, 149 nM, and 1127 nM for **p110α**, **CK2**, and **CK2α2** in lipid kinase assay, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SGC-CK2-1

Cat. No.: HY-139004

SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active **CK2** chemical probe with exclusive selectivity for both human CK2 isoforms, with IC_{50}s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Silmitasertib

(CX-4945)

Cat. No.: HY-50855

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent **CK2** inhibitor, with IC_{50} values of 1 nM against CK2α and CK2α'.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Silmitasertib sodium salt

(CX-4945 sodium salt)

Cat. No.: HY-50855B

Silmitasertib sodium salt is an orally bioavailable, highly selective and potent **CK2** inhibitor, with IC_{50} values of 1 nM against CK2α and CK2α'.



Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SR-1277

Cat. No.: HY-108907

SR-1277 is a potent, selective and ATP competitive **CK1δ/ε** inhibitor, with IC_{50}s of 49 nM and 260 nM, respectively. SR-1277 also inhibits **FLT3**, **CDK4/cyclin D1**, **CDK6/cyclin D3** and **CDK9/cyclin K**, with IC_{50}s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR-3029

Cat. No.: HY-100011

SR-3029 is a potent and ATP competitive **CK1δ** and **CK1ε** inhibitor, with IC_{50}s of 44 nM and 260 nM, respectively, and K_is of 97 nM for both kinases.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

SSTC3

Cat. No.: HY-120675

SSTC3 is a **casein kinase 1α (CK1α)** activator (K_d = 32 nM) that inhibits **WNT** signaling (EC_{50} = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TA-01

Cat. No.: HY-100114

TA-01 is a potent **CK1** and **p38 MAPK** inhibitor, with IC_{50}s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-715

Cat. No.: HY-10456

TAK-715 is an orally active and potent **p38 MAPK** inhibitor with IC_{50}s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits **casein kinase I (CK1δ/ε)** to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TBB

(NSC 231634; Casein Kinase II Inhibitor I)

Cat. No.: HY-14394

TBB is a cell-permeable and ATP-competitive **CK2** inhibitor with an IC_{50} of 0.15 μM for rat liver CK2.

Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TBCA

Cat. No.: HY-110052

TBCA is a highly selective **CK2 (casein kinase II)** inhibitor with an IC_{50} of 110 nM and a K_i of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg

TMCB

Cat. No.: HY-103384

TMCB is a selective, ATP-competitive **CK2 (casein kinase II)** inhibitor with distinct K_i values of 83 nM and 21 nM for the two different catalytic CK2 subunits α and α', respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

TMX-4113

Cat. No.: HY-145320

TMX-4113 is a degrader of phosphodiesterase 6D (**PDE6D**) and casein kinase 1α (**CK1α**). TMX-4113 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TMX-4116

Cat. No.: HY-145322

TMX-4116 is a casein kinase 1α (**CK1α**) degrader. TMX-4116 shows the degradation preference for CK1α with DC_{50}s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TTP 22

Cat. No.: HY-15479

TTP 22 is a potent **CK2** inhibitor, with an IC_{50} of 100 nM and a K_i of 40 nM.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg